Please login to the form below

Not currently logged in
Email:
Password:

Dermira

This page shows the latest Dermira news and features for those working in and with pharma, biotech and healthcare.

Dermira craters as acne drug fails late-stage test

Dermira craters as acne drug fails late-stage test

Dermira craters as acne drug fails late-stage test. The US biotech lost two-thirds of its share value after the news broke. ... Dermira’s acne candidate DRM01 failed to hit the mark in two phase III trials and this has left the company with a big hole

Latest news

  • Roche out-licenses lebrikizumab rights to Dermira Roche out-licenses lebrikizumab rights to Dermira

    Roche out-licenses lebrikizumab rights to Dermira. Swiss drug maker stands to receive $80m upfront for the drug. ... Roche has opted to out-license the bulk of the rights to its IL-13 inhibitor lebrikizumab to dermatology company Dermira in a deal valued

  • UCB moves Cimzia into phase III trials for psoriasis UCB moves Cimzia into phase III trials for psoriasis

    UCB moves Cimzia into phase III trials for psoriasis. Firm collaborating with Dermira to test efficacy and safety of drug. ... Dr Iris Loew-Friendrich, chief medical officer and executive VP at UCB, commented: “ Our collaboration with Dermira and the

  • Archive listing

    Dermira craters as acne drug fails late-stage test.

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Roche has licensed a monoclonal antibody in phase II to Dermira, a dermatology company. ... This is probably as much as Dermira can afford. It estimates that the development cost will be $200m to get the top line phase IIb study results and has cash

  • Deal Watch September 2016 Deal Watch September 2016

    Royalty range 4 -10%. 150. Dermira / Maruho. Licence. Exclusive licence to DRM04 topical anticholinergic for axillary hyperhidrosis; upfront $25m.

  • Pharma deals during July 2014 Pharma deals during July 2014

    dermatology specialist Dermira to develop Cimzia for psoriasis in the US, Canada and the EU. ... Based on promising phase 2 data in psoriasis, Dermira will be responsible for phase III costs and will receive up to $49.5m from UCB in development and

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    107. UCB/ Dermira. Licence ††. Cimzia (certolizumab pegol) - drug repurposing (p2 for psoriasis).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics